BETHLEHEM, PA – January 13, 2015 – B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, announced today the launch of Nutrilipid^® 20% (I.V. fat emulsion) for parenteral nutrition therapy.

The launch of Nutrilipid 20% will help alleviate the short supply of lipid emulsion products the U.S. has seen over the past few years. It will be available in flexible containers that are not made with natural rubber latex, DEHP or PVC. B.Braun’s clinical nutrition compounding offering now also includes Sterile Water for Injection USP in TITAN™ XL 2L and 3L containers, the only large-volume, flexible containers approved in the U.S. that are not made with natural rubber latex, DEHP or PVC.

“Through our state-of-the-art production facility, we are committed to providing quality clinical nutrition products so that patients have access to parenteral nutrition they often critically need,” said Rick Williamson, Vice President of Pharmaceutical Marketing at B.Braun.

About B. Braun
B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The Company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. Guided by its “Sharing Expertise^®” philosophy, B.Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.

The B.Braun Group of Companies in the U.S. includes B.Braun, B.Braun Interventional Systems, Aesculap^® and CAPS^®. B.Braun’s U.S. headquarters is located in Bethlehem, Pennsylvania. The B.Braun Group of Companies employs more than 50,000 employees in more than 60 countries throughout the world. To learn more about B.Braun visit www.BBraunUSA.com.